|
2026
|
Invention
|
Therapeutic agents for neurodegenerative diseases.
The present disclosure provides for treating ... |
|
|
Invention
|
Treatment of late-onset neurodegenerative diseases in heterozygous npc1 gene mutation carriers.
... |
|
2025
|
Invention
|
Therapeutic agents for improved mobility and cognitive function and for treating neurodegenerativ... |
|
|
Invention
|
Acetyl-leucine for treating parkinson´s disease. The present disclosure provides for treating Par... |
|
2024
|
Invention
|
Deuterated analogs of acetyl-leucine.
The present disclosure provides compounds represented by F... |
|
|
Invention
|
Pharmaceutical compositions and uses directed to lysosomal storage disorders. The present disclos... |
|
2023
|
Invention
|
Branched-chain amino acid derivatives to treat disease. The present disclosure provides compounds... |
|
|
P/S
|
Pharmaceutical preparations for activating cellular function for treating diseases, disorders, an... |
|
|
P/S
|
Pharmaceutical preparations for activating cellular
function; pharmaceutical preparations for th... |
|
|
Invention
|
Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, fo... |
|
2021
|
Invention
|
The combination of acetyl leucine and 4-aminopyridine or acetazolamide for treating ataxia.
The ... |
|
|
Invention
|
The combination of acetyl leucine and 4-aminopyridine or acetazolamide for treating ataxia. The p... |
|
|
Invention
|
Treatment of late-onset neurodegenerative diseases in heterozygous npc1 gene mutation carriers. T... |
|
|
Invention
|
Treatment of late-onset neurodegenerative diseases in heterozygous npc1 gene mutation carriers. N... |
|
2020
|
Invention
|
Combination therapy with acetyl-leucine and miglustat. The present disclosure provides methods of... |
|
|
Invention
|
Leucine, acetyl leucine, and related analogs for treating disease.
The present disclosure provid... |
|
|
Invention
|
Leucine, acetyl leucine, and related analogs for treating disease. The present disclosure provide... |
|
2019
|
Invention
|
Deuterated analogs of acetyl-leucine. 13 is about 15% or more. The present disclosure also provid... |
|
|
Invention
|
Deuterated analogs of acetyl-leucine. The present disclosure provides compounds represented by Fo... |
|
|
Invention
|
Therapeutic agents for treating restless leg syndrome. The present disclosure provides for treatm... |
|
|
Invention
|
Therapeutic agents for treating restless legs syndrome. The present disclosure provides for treat... |
|
2018
|
Invention
|
Treatment for migraine. A first aspect of the invention relates to leucine, acetyl-leucine, or a ... |
|
|
Invention
|
Use of acetyle-leucine to prevent and/or treat migraine. A first aspect of the invention re... |
|
|
Invention
|
Therapeutic agents for neurodegenerative diseases. The present disclosure provides for treating n... |
|
|
Invention
|
Treatment of restless leg syndrome (rls) with leucine, acetyle-leucine, or a pharmaceutically acc... |
|
|
P/S
|
Pharmaceutical preparations; pharmaceutical preparations for
activating cellular function; pharm... |
|
2017
|
P/S
|
Pharmaceutical preparations; Pharmaceutical preparations for activating cellular function; Pharma... |
|
|
Invention
|
Acetyl-leucine for neurodegenerative diseases. The present disclosure provides for treating neuro... |
|
|
Invention
|
Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive ... |
